The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Updated results from DREAMM-8: insights from a long-term responder analysis
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses updated results from the DREAMM-8 trial (NCT04484623) investigating belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). He highlights that patients receiving BPd had higher rates of sustained measurable residual disease (MRD) negativity than those in the control arm, and outlines characteristics that resulted in a greater likelihood of achieving sustained MRD negative status. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
DREAMM-8 is a prospective randomized trial which confirmed the superiority of the combination of belantamab mafodotin with pomalidomide and dexamethasone over the control arm in patients who have received at least one prior line of therapy. Patients should have been exposed, pretreated, with lenalidomide, and several of them were also pre-treated with anti-CD38 monoclonal antibody...
DREAMM-8 is a prospective randomized trial which confirmed the superiority of the combination of belantamab mafodotin with pomalidomide and dexamethasone over the control arm in patients who have received at least one prior line of therapy. Patients should have been exposed, pretreated, with lenalidomide, and several of them were also pre-treated with anti-CD38 monoclonal antibody. The progression-free survival was 33 months, and it was superior in the belantamab mafodotin arm. Furthermore, further analysis indicated that there is a subset of patients who enjoyed very long progression-free survival and these were patients who were able to achieve not only complete response but also MRD negative status and sustained MRD negative status which was indicated by being in MRD negative status for at least 12 months. So these patients had an excellent outcome with very few relapses and actually we were able to identify characteristics of patients who are more likely to achieve the long-term MRD negativity. These were patients who have received second-line therapy in the study, patients who had standard-risk myeloma, patients who were less refractory to prior therapies, and patients who had low ISS stage.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
